NTT: CEOs See Major Opportunities in Emerging Technologies to Tackle Social Challenges
18.12.2020 07:18:00 EET | Business Wire | Press release
WSJ Intelligence undertook a new international CEO survey for global technology and business solution provider NTT (TOKYO:9432). The survey focused on the dire necessity for complex digital technologies that have made it possible for businesses and societies to keep functioning amid the Covid-19 global pandemic.
WSJ Intelligence's global survey included 352 CEOs of large corporations representing ten major industries, across fifteen countries. The CEOs surveyed were asked about their corporation's role in society, their social-impact strategies, the stakeholders involved, and how those strategies were affected by the pandemic. This survey also examined the CEOs' confidence in a range of new and emerging technologies, and how those innovations might help the world to tackle enormous social challenges, such as the global supply chain, the future of work and health and well-being.
Key Findings:
- 56% of respondents believe corporations generate value by earning profits in a sustainable way that includes minimizing harm to society;
- 80% of stakeholder-centric executives say they pursue parallel financial and community outcomes, and see social-impact strategies as essential to financial returns;
- Technology powers the tools and opportunities to tackle social issues, but can also disrupt social stability through the rapid spread of false or misleading information;
- Cybersecurity is the only technology that a majority of executives consider fully adequate for their social-impact strategy; however adoption of cybersecurity technologies is not fast enough or sufficiently complete yet
- High-performance communications networks, followed by cloud computing and advanced analytics, are identified by CEOs as promising technologies with which to address social issues.
As the world continues to combat Covid-19 and plan for recovery, digital technology and social-impact programs will help to create the "new normal." The recovery from Covid-19 presents every organization with the opportunity to think in new ways and accelerate digital transformation.
About This Research
This research was conducted in July/August 2020 among CEOs across 15 countries, who participated in an online survey that aimed to understand how they viewed their company's responsibility to contribute, visibly and substantively, to achieving societal goals. Globally, 352 CEOs at companies with more than US$500M in revenue (with 75 of U.S. respondents at companies with more than $1BN) participated in quantitative research across 10 industries. "Investor-centric" respondents were defined as those whose view of the corporation is strictly to create value for shareholders by earning profit. "Stakeholder-centric" respondents answered either: "To create value for all stakeholders by earning profits in a sustainable way, which includes minimizing the harm that the business causes to society" or "Contribute to solutions for the challenges confronting people and society as a means of earning profits and generating long-term stakeholder value", when asked for their view of the role of the corporation in global society today.
[Reference]
READ THE WHITE PAPER (PDF: 2MB)
About WSJ Intelligence
WSJ Intelligence conducts bespoke and secondary research for brands and client brands of The Wall Street Journal | Barron's Group. Through rigorous analysis, WSJ Intelligence provides insights that are relevant, timely, and reliable.
About NTT
NTT believes in contributing to society through our business operations. We help people, clients and communities move confidently into the digital future and shape a better world. Our services include digital business consulting, technology and managed services for cybersecurity, applications, workplace, cloud, data centers and networks. As a top-5 global technology and business solutions provider, our diverse team of over 300,000 people operates in 80+ countries and regions and delivers services to over 190 of them.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201217006234/en/
Contact information
Yuzo Aramaki
Associate Manager
Press Relations of NTT Corporation
Mail: ntt-cnr-ml@hco.ntt.co.jp
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
VerSprite Launches Fork and Knife: AI-Driven Threat Modeling and Adversarial Testing Built for the Speed of Modern Software27.6.2026 00:28:00 EEST | Press release
VerSprite, a global leader in risk-based threat modeling and the firm behind the PASTA (Process for Attack Simulation and Threat Analysis) methodology, today announced the general availability of Fork (www.forktm.com), a continuous application threat modeling platform, alongside Knife, an AI-led, human-on-the-loop adversarial testing platform for web applications and web API endpoints. Together, the two products operationalize a new model for product security—one where applications are securely designed, continuously modeled, and actively tested as part of the build process itself. The launch addresses a problem every security leader knows but few tools have solved: threat modeling is essential, never more so than in an AI-driven era, yet it has remained slow, manual, and anchored to frameworks designed for a different threat landscape. The problem: threat modeling matters more than ever—and most tools are stuck in 2005 For two decades, application threat modeling has leaned heavily on
Venture Global Announces Closing of $1.5 Billion Senior Secured Vessel Financing Facility26.6.2026 23:30:00 EEST | Press release
Venture Global, Inc. (NYSE: VG) announced today that its wholly-owned subsidiary, Venture Global Shipping Holdings, LLC (“VGSH”), has entered into a Credit and Guaranty Agreement providing for a senior secured term loan facility (the “Facility”) in an aggregate principal amount of up to $1,500,000,000. The Facility will mature on June 26, 2032. Deutsche Bank and ING acted as coordinating lead arrangers for the Facility. ING also serves as facility agent and security trustee. VGSH intends to use the net proceeds from the Facility for general corporate purposes, including to reimburse Venture Global LNG, Inc. for payments previously made by it or its affiliates in connection with the acquisition of nine LNG carriers, funding certain reserve accounts, and paying transaction fees and expenses. About Venture Global Venture Global is an American producer and exporter of low-cost U.S. liquefied natural gas (“LNG”) with over 100 MTPA of capacity in production, construction, or development. Ven
Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 21:00:00 EEST | Press release
Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solution – uses digital twin technology to identify vulnerable customers and recommend explainable next-best actions for fro
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
